Stichting Sanquin Bloedvoorziening (SB)

Sanquin Research (SR) is actively involved in the training of bachelor-, master- and PhD-students. SR employs 17 full professors and multiple associate professors. Currently, approximately 75 PhD students in all stages of their study perform their studies at SR. They enroll in the (post)graduate school of the Academic Medical Centre (AMC) of the University of Amsterdam (UvA). The research division is well equipped and performs basic and translational research in the field of transfusion medicine, haematology and immunology.

Role and Commitment of key persons (including supervisors)

Robin van Bruggen (SB1) will be the direct supervisor of ESR3, Emile van den Akker (SB2) will be the direct supervisor of ESR4. Marieke von Lindern (SB-2) is the training supervisor of EVIDENCE, and will also supervise the thesis of ESR4

Key Research Facilities, Infrastructure and Equipment

We use state-of-art mass spectroscopy (Orbitrap), (life) cell imaging, flow cytometry (including Imagestream), high throughput gene expression, and advanced cell culture. GMP conditions are being established for the culture of red cells for transfusion. Weekly seminars from (inter)national researchers and specific courses for young investigators render Sanquin an excellent research and training environment.

Status of Research Premises

Sanquin Research is the independent research institute of the not-for-profit Dutch Blood Supply Organisation Sanquin, via the Landsteiner Laboratory contract it is legally associated with the AMC/UvA. Research is to a large extent financed by external funds.

Previous Involvement in Research and Training Programmes

Robin van Bruggen (SB1) is a lecturer for Master, PhD student and postdoctoral student courses on national level (e.g. Lecturer in the Sanquin Science course for PhD students and postdoctoral students starting at Sanquin Research (2012-2018).

Marieke von Lindern (SB2) is a lecturer and organiser of scientific courses on national and European level. PI in previous ETNs: Signals to genes to phenotypes, 2000 – 2004; EURYTHRON, 2005-2008. Recent research projects: Selective mRNA translation controls erythropoiesis, LSBR: 2012-2016; Control of erythropoiesis by iron dependent expression of protein isoforms. LSBR: 2013-2017.

Emile van den Akker (SB2) is PI of several national grants among which From in vitro erythropoiesis to transfusion, LSBR: 2013-2017; Towards blood cell pharming: Band 3 macro complex assembly during enucleation and reticulocyte maturation. PPO-C: 2011-2015.

Current Involvement in Research and Training Programmes

SB1 coordinates several national grants of the Ministry of Health (Mechanism and in vivo relevance of PS exposure on human erythrocytes. (PPO-C), 2010-2014; Identification of removal signals on donor erythrocytes after transfusion in MDS patients. (PPO-C), 2013-2017; Understanding donor RBC removal in the critically ill. (PPO-C), 2013-2017; Genetic and functional diversity of immunoreceptors in sickle disease.(PPO-C), 2013-2017.). Currently, a partner in the EU-ITN RELEVANCE.

SB2-MvL coordinates From iPS to transfusion-ready erythrocytes, ZonMW-TAS, 2014-2022, Bone marrow failure: disease mechanisms and novel treatment options PPO-C 2015-2019, Bioreactor development for cellular therapeutic products: Large Scale Production of Red Cells for Transfusion Purposes PPO-C 2017-2022. She is currently supervising 4 PhD students. SB2-EA is PI of current grants SMIM1, the VEL-antigen, a novel regulator of erythropoiesis, LSBR: 2014-2018; and is currently supervising 3 PhD students and 1 postdoctoral fellow.

Relevant Publications and/ or Research/ Innovation Product